← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2001Last known activity
Nov 29, 2024
Timeline
1990s
- Jun 1, 1993
ARCAGY-GINECO— Founded
Drugs by trial phase (40 distinct, 47 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (10 own, 0 via acquisition)
Phase 2 (26 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma, Clear Cell
- Adenomyoepithelioma
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Carcinosarcoma
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Genital Diseases, Female
- Hypersensitivity
- Mixed Tumor, Mullerian
- Neoplasm Metastasis
- Neoplasms
- Neurotoxicity Syndromes
- Ovarian Diseases
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Recurrence
- Sex Cord-Gonadal Stromal Tumors
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT06715241Lead sponsorPhase 2Nov 29, 2024
- NCT06476184Lead sponsorPhase 3Aug 5, 2024
- NCT05201547Lead sponsorPhase 3Apr 15, 2022
- NCT05183984Lead sponsorPhase 2Feb 1, 2022
- NCT05041842CollaboratorPhase 2Nov 15, 2021
- NCT04713514Lead sponsorPhase 2Aug 5, 2021
- NCT04602377Lead sponsorPhase 2Nov 30, 2020
- NCT04256213Lead sponsorN/AFeb 29, 2020
- NCT04015739Lead sponsorPhase 2Feb 12, 2019
- NCT03745950Lead sponsorPhase 2Feb 1, 2019
- NCT03745950Overall official - principal investigatorPhase 2Feb 1, 2019
- NCT03651206Lead sponsorPhase 2/Phase 3Jan 31, 2019
- NCT03752216Lead sponsorPhase 4Dec 31, 2018
- NCT03275506Lead sponsorPhase 2Feb 28, 2018
- NCT03249142Lead sponsorPhase 1/Phase 2Oct 18, 2017
Details
- Founded
- Paris, FR Jun 1, 1993
- Last known activity
- Nov 29, 2024
Notes
CRO